There are a lot of causes to move to the significant exchanges, such as NYSE or Nasdaq, from an more than-the-counter (OTC) exchange.
Even though OTC listing is less expensive with significantly less stringent requirements than the significant exchanges, there’s a great deal to achieve from uplisting.
These stricter reporting requirements give retail investors a higher comfort level to invest. Beyond comfort, these requirements also let institutional investors to get the stocks inside their mandates.
Meanwhile, pot stocks grow to be a great deal a lot more liquid on significant exchanges than they are more than-the-counter.
Nonetheless, not every single cannabis business can list their shares on NYSE or NASDAQ. Cannabis companies conducting business in the U.S. can not list on a key exchange. Certainly, marijuana remains a Schedule I drug in the U.S. at the federal level. As such, NYSE and Nasdaq only grant listing to companies with cannabis operations outdoors the U.S.
Not all pot providers can list
In 2018, five cannabis companies uplisted. HEXO Corp. looks to comply with suit before the finish of the year. But there a couple a lot more that match the bill.
Industry cap.: $750 million.
CannTrust Holdings (TSX: TRST.TO) May have it is ducks in a row for listing on a key U.S. exchange.
The business boasts a 60,000-square-foot Vaughan Ontario facility. Meanwhile its concentrate is on bringing down charges at the company’s upcoming 1-million-square-foot Niagara Greenhouse hydroponic develop farm.
Listing up could be a fantastic move for CannTrust. Maintaining in thoughts, the upward move’s been a boon to some and anticlimactic for other producers in the space.
Industry cap.: $600 million.
OrganiGram Holdings (TSXV: OGI.V)
Despite the fact that the business have some scaling up to do, OrganiGram could quickly be amongst the top rated 10 cannabis producers.